Compare Stocks: IMNM, ARWR, IBRX, and KYMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$62.35 -2.9%	$80.83	$34.61 ▼ $95.49	$8.78B	1.29	2.30 million shs	2.25 million shs
IBRX ImmunityBio	$10.38 +1.0%	$8.02	$1.95 ▼ $12.43	$11.00B	0.02	20.79 million shs	16.79 million shs
IMNM Immunome	$21.17 +1.3%	$25.35	$12.41 ▼ $30.06	$2.40B	2.55	1.36 million shs	1.22 million shs
KYMR Kymera Therapeutics	$109.85 +2.3%	$114.62	$55.26 ▼ $130.05	$9.13B	1.98	740,851 shs	729,685 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-2.62%	-25.65%	-25.83%	+77.71%
IBRX ImmunityBio	0.00%	+21.80%	+27.23%	+15.38%	+304.72%
IMNM Immunome	0.00%	-2.38%	-21.90%	-12.55%	+68.82%
KYMR Kymera Therapeutics	0.00%	-4.07%	-8.52%	-6.42%	+85.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$62.35 -2.9%	$80.83	$34.61 ▼ $95.49	$8.78B	1.29	2.30 million shs	2.25 million shs
IBRX ImmunityBio	$10.38 +1.0%	$8.02	$1.95 ▼ $12.43	$11.00B	0.02	20.79 million shs	16.79 million shs
IMNM Immunome	$21.17 +1.3%	$25.35	$12.41 ▼ $30.06	$2.40B	2.55	1.36 million shs	1.22 million shs
KYMR Kymera Therapeutics	$109.85 +2.3%	$114.62	$55.26 ▼ $130.05	$9.13B	1.98	740,851 shs	729,685 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-2.62%	-25.65%	-25.83%	+77.71%
IBRX ImmunityBio	0.00%	+21.80%	+27.23%	+15.38%	+304.72%
IMNM Immunome	0.00%	-2.38%	-21.90%	-12.55%	+68.82%
KYMR Kymera Therapeutics	0.00%	-4.07%	-8.52%	-6.42%	+85.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.64	Moderate Buy	$98.31	57.67% Upside
IBRX ImmunityBio	2.86	Moderate Buy	$14.20	36.80% Upside
IMNM Immunome	2.79	Moderate Buy	$34.25	61.79% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$134.46	22.40% Upside

Current Analyst Ratings Breakdown

Latest IMNM, ARWR, IBRX, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	KYMR Kymera Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $150.00
9/30/2026	IMNM Immunome	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$24.00
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/24/2026	ARWR Arrowhead Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$74.00
9/23/2026	KYMR Kymera Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$140.00
9/22/2026	KYMR Kymera Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$132.00 ➝ $152.00
9/21/2026	IMNM Immunome	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
9/14/2026	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$123.00 ➝ $144.00
9/10/2026	KYMR Kymera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$180.00
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/8/2026	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$108.00

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	10.59	$0.12 per share	537.60	$3.64 per share	17.13
IBRX ImmunityBio	$113.29M	97.11	N/A	N/A	($0.51) per share	-20.35
IMNM Immunome	$6.94M	346.47	N/A	N/A	$5.75 per share	3.68
KYMR Kymera Therapeutics	$39.21M	232.95	N/A	N/A	$19.42 per share	5.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	11/24/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)

Latest IMNM, ARWR, IBRX, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
IBRX ImmunityBio	N/A	5.72	5.70
IMNM Immunome	N/A	15.08	15.08
KYMR Kymera Therapeutics	N/A	10.34	10.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
IBRX ImmunityBio	8.58%
IMNM Immunome	44.58%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
IBRX ImmunityBio	66.10%
IMNM Immunome	7.21%
KYMR Kymera Therapeutics	15.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	711	140.86 million	135.79 million	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable

IMNM, ARWR, IBRX, and KYMR Headlines

Recent News About These Companies

Kymera Therapeutics Officer Nello Mainolfi Files Form 144 for 30,000 Share Sale

October 3 at 11:08 PM | kalkinemedia.comK

Kymera Therapeutics (NASDAQ:KYMR) Stock: Insider Nello Mainolfi Sells 30,000 Shares

October 3 at 4:08 AM | americanbankingnews.com

B.Riley keeps Buy rating for Kymera Therapeutics stock

October 2 at 3:05 PM | ad-hoc-news.deA

Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares of Stock

October 2 at 5:07 AM | insidertrades.com

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Company Stock

October 1, 2026 | marketbeat.com

Kymera Therapeutics stock reports 465.2 percent revenue growth

September 30, 2026 | ad-hoc-news.deA

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

September 30, 2026 | prnewswire.com

Kymera Therapeutics en foro Stifel: ruta acelerada para su fármaco líder

September 24, 2026 | mx.investing.com

Kymera Therapeutics al forum Stifel: percorso accelerato per il farmaco principale

September 24, 2026 | it.investing.com

Piper Sandler维持Kymera Therapeutics股票"增持"评级，目标价$140

September 23, 2026 | cn.investing.com

Piper Sandler conferma il rating su Kymera Therapeutics a $140

September 23, 2026 | it.investing.com

Stifel Nicolaus Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock

September 22, 2026 | marketbeat.com

Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR

September 22, 2026 | marketbeat.com

Kymera Therapeutics stock gains as biotech sector strength follows recent earnings

September 18, 2026 | ad-hoc-news.deA

J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

September 18, 2026 | theglobeandmail.com

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Intuitive Surgical (ISRG)

September 15, 2026 | theglobeandmail.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by Brokerages

September 15, 2026 | marketbeat.com

BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123

September 14, 2026 | marketscreener.comM

Kymera Therapeutics, Inc. $KYMR Shares Sold by California State Teachers Retirement System

September 14, 2026 | marketbeat.com

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 11, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMNM, ARWR, IBRX, and KYMR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$62.35 -1.84 (-2.87%)

Closing price 04:00 PM Eastern

Extended Trading

$63.00 +0.64 (+1.03%)

As of 06:28 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ImmunityBio NASDAQ:IBRX

$10.38 +0.10 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$10.43 +0.05 (+0.52%)

As of 06:39 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Immunome NASDAQ:IMNM

$21.17 +0.27 (+1.29%)

Closing price 04:00 PM Eastern

Extended Trading

$21.20 +0.03 (+0.14%)

As of 05:16 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Kymera Therapeutics NASDAQ:KYMR

$109.85 +2.46 (+2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$109.74 -0.11 (-0.10%)

As of 05:03 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, ARWR, IBRX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, ARWR, IBRX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, ARWR, IBRX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMNM, ARWR, IBRX, and KYMR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

ImmunityBio NASDAQ:IBRX

Immunome NASDAQ:IMNM

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, ARWR, IBRX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, ARWR, IBRX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, ARWR, IBRX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMNM, ARWR, IBRX, and KYMR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

ImmunityBio NASDAQ:IBRX

Immunome NASDAQ:IMNM

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools